Head-to-head · free
Neuronetics, Inc. vs Stryker Corporation
STIM vs SYK — return on capital, cash generation, margins and balance sheet side by side.
STIM
2 / 7
measures where STIM leads
SYK
5 / 7
measures where SYK leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | STIM · FY2025 | SYK · FY2025 |
|---|---|---|
| Revenue | $149.2M | $5.9B |
| Net income | (39.0M) | $654.0M |
| Revenue growth (yearly, multi-year) | 28.1% | 10.4% |
| Free cash flow | — | $4.3B |
| Free cash flow margin | — | 73.0% |
| Net cash / (debt) | — | — |
| ROIC | — | 9.6% |
| Return on equity | -155.7% | 15.1% |
| Gross margin | 48.5% | 64.0% |
| Operating margin | -21.1% | 20.1% |
| Net debt / EBITDA | -1.35x | 1.95x |
Figures are as reported by each company; latest fiscal year shown.
Where Neuronetics, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Stryker Corporation's cash went (FY2025)
- Capital spending
- $761.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free